TOP > 外国特許検索 > ANTIBODY FRAGMENT AND BISPECIFIC ANTIBODY COMPRISING SAID ANTIBODY FRAGMENT

ANTIBODY FRAGMENT AND BISPECIFIC ANTIBODY COMPRISING SAID ANTIBODY FRAGMENT

外国特許コード F200010005
整理番号 (S2018-0495-N0)
掲載日 2020年1月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP015528
国際公開番号 WO 2019198731
国際出願日 平成31年4月9日(2019.4.9)
国際公開日 令和元年10月17日(2019.10.17)
優先権データ
  • 特願2018-075339 (2018.4.10) JP
発明の名称 (英語) ANTIBODY FRAGMENT AND BISPECIFIC ANTIBODY COMPRISING SAID ANTIBODY FRAGMENT
発明の概要(英語) In the present invention, an antibody fragment that binds specifically to human HER2 comprises the amino acid sequence of a single polypeptide chain having the structure in formula (1). Formula (1): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (In the formula, FR1, FR2, FR3, and FR4 are framework regions, and CDR1, CDR2, and CDR3 are complementarity determining regions and satisfy at least one of conditions (I) to (III): (I) CDR1 comprises an amino acid sequence represented by any of SEQ ID NOs: 5–11, 53–55, and 59–64, comprises an amino acid sequence containing one or more deletions, substitutions, or additions in an amino acid sequence represented by any of SEQ ID NOs: 5–11, 53–55, and 59–64, or comprises an amino acid sequence having at least 80% identity with an amino acid sequence represented by any of SEQ ID NOs: 5–11, 53–55, and 59–64; (II) CDR2 comprises an amino acid sequence represented by any of SEQ ID NOs: 12–18, comprises an amino acid sequence containing one or more deletions, substitutions, or additions in an amino acid sequence represented by any of SEQ ID NOs: 12–18, or comprises an amino acid sequence having at least 80% identity with an amino acid sequence represented by any of SEQ ID NOs: 12–18; and (III) CDR3 comprises an amino acid sequence represented by any of SEQ ID NOs: 19–25, 56–58, and 65–84, comprises an amino acid sequence containing one or more deletions, substitutions, or additions in an amino acid sequence represented by any of SEQ ID NOs: 19–25, 56–58, and 65–84, or comprises an amino acid sequence having at least 80% identity with an amino acid sequence represented by any of SEQ ID NOs: 19–25, 56–58, and 65–84.)
従来技術、競合技術の概要(英語) BACKGROUND ART
Cancer (malignant tumor) as the safety with respect to the therapeutic agent, immunotherapy is used. Immunotherapy for cancer, cancer-specific cytotoxic activity of the antibody are used.
Human epidermal growth factor Receptor 2 (HER2) is present on the cell surface glycoprotein receptor tyrosine kinase (molecular weight of about 185kDa) and, EGFR2, ErbB2, CD340, or also referred to as the NEU. HER2 Is deficient or a variant thereof including breast cancer including a plurality of over-expressed in cancer, has attracted attention as a therapeutic target. HER2 Antibody is targeted, targeting the expected therapeutic effect of the cancer cell surface antigens one.
Has a basic structure of the antibody, the heavy and light chain subunit by a disulfide bond is formed by, such as the type of polymer since the amount of the IgG, is not able to penetrate the deep portion of the tumor. Therefore, the variable region of the low molecular weight fragments of the antibody is currently under development.
In recent years, Hamers-Casterman et al. in an animal such as a family or a dromedary germlining germlining, only the heavy chain CH1 domain does not include the presence of antibody was reported (Non-Patent Document 1). Camel (single Variable domain of the Heavy chain of a Heavy-chain camel antibody variable region fragment of an antibody derived from: VHH) is, in spite of a single domain, a high affinity, has a high specificity. Thus, obtained by immunization of animals and plants llama antibody phage display library group such as in vitro selection operation is performed that specifically binds to a variety of targets are VHH is obtained (non-patent document 2, 3).
On the other hand, in order to improve the affinity for the antigen, the antibody or a multivalent multimerisation also known technology. Harwood et al. for a three-dimer domain are known as anti-CD3 scFv1 antibody collagen XVIIItrimerization domain 3 and the anti-EGFR VHH molecule can be a fusion molecule, EGFR trivalent to design a recombinant antibody, a recombinant antibody according to the same domain is composed of a single one value higher than the recombinant antibodies of exerting damage reported (Non-Patent Document 4).
IgG type antibodies in a conventional, natural killer cells than the high activity of the T cells cannot be used, the T cells can be used a low molecular weight antibodies are developed, a low molecule, and bind to cells having a valence of 1, a low affinity for antigen binding.
To increase the binding affinity of the antibody and antigen antibody designed to provide enhanced active injury by a multi-value, is considered to be an effective approach, the heavy and light chain of the linker between the shortening of the sequence, removing a multi-value multi-value design is effective to some extent the formation of the association of the (non-patent document 5, 6), only a single multi-value association is formed has not been a design.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOHOKU UNIVERSITY
  • UNIVERSITY OF THE RYUKYUS
  • 発明者(英語)
  • UMETSU, Mitsuo
  • SUGIYAMA, Aruto
  • NAKAZAWA, Hikaru
  • NIIDE, Teppei
  • KISHIMOTO, Hidehiro
  • MURAKAMI, Akikazu
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までご連絡ください。

PAGE TOP

close
close
close
close
close
close